Heghine Khachatryan։ Age-Adjusted D-Dimer Thresholds for Safer and Smarter VTE Rule-Out
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared RPTH’s post on LinkedIn:
”A very important and practical review published in the RPTH Journal highlights a concept that deserves wider clinical attention: age-adjusted D-dimer thresholds.
D-dimer levels naturally increase with age, meaning that the traditional fixed cut-off may lead to false positives and unnecessary imaging, especially in older patients.
Using age-adjusted D-dimer values (Age × 10 µg/L for patients >50 years) helps maintain safety in ruling out VTE while reducing unnecessary CT scans, radiation exposure, and healthcare costs.
This is a clear example of how smarter interpretation of existing diagnostic tests can significantly improve clinical decision-making.”
RPTH Journal shared a post on LinkedIn about a recent article by Tayssir Fatah et al, published in RPTH Journal:
”Is the D-dimer cut-off we use every day actually outdated?
We order D-dimer constantly to rule out VTE. But here’s the problem: D-dimer naturally rises with age.
That means the standard cut-off becomes less specific every year a patient gets older, leading to more false positives and more unnecessary CT scans.
This RPTH review revisits one of the most practical changes in thrombosis diagnostics:
Age-adjusted D-dimer thresholds.
The concept is simple:
For patients >50 years, use Age × 10 μg/L instead of a fixed cut-off.
Why this matters
- It maintains safety for ruling out VTE.
- It reduces unnecessary imaging.
- It cuts radiation exposure and healthcare costs.
- It improves emergency department workflow and patient experience.
Yet despite strong evidence, adoption is still inconsistent worldwide.
So the real question becomes:
- Why hasn’t this become universal practice yet?
- Do your local protocols use age-adjusted D-dimer?
- What barriers still exist in implementation?
Sometimes the most impactful innovation isn’t a new drug, it’s using existing tests smarter.”
Title: Raising the D-dimer bar: a narrative review of the age-adjusted D-dimer threshold
Authors: Tayssir Fatah, Judith Catella, Christophe Nougier, Hamdi Rezigue
Read Full Article on RPTH Journal

Other posts featuring Heghine Khachatryan on Hemostasis Today.
-
Apr 15, 2026, 04:06Brenda Pleasant: Insights from the HFA Symposium on Hemophilia Care
-
Apr 15, 2026, 03:43Lexy Halloran: Addressing Diagnostic Inequities in Women with Chronic Conditions
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE